The options market is bracing for fireworks. When Novo Nordisk delivers its second-quarter results on August 5, derivatives pricing implies a roughly 8 percent swing in the Danish drugmaker’s shares — a level of anticipated volatility that reflects just how much hangs on the print. The company arrives at the report battered but not broken: its stock closed Friday at EUR 40.90, down 8.48 percent in a single session, yet still holding 1.35 percent above its 200-day moving average of EUR 40.35.
That Friday slide marked the steepest one-day drop since February, triggered by a clinical setback that has forced investors to reassess both the pipeline and the near-term earnings trajectory. The question now is whether the GLP-1 franchise — the engine that built Novo’s modern valuation — can carry the stock through what has become a bruising stretch.
A Trial That Worked Biologically but Failed Clinically
The source of the sell-off was Ziltivekimab, an experimental cardiovascular drug that missed its primary endpoint in the Phase 3 ZEUS study. The placebo-controlled trial enrolled more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammatory markers (hsCRP of at least 2 mg/l), all receiving monthly 15-milligram doses. The goal was a reduction in major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or stroke. The result: a hazard ratio of 0.99, meaning essentially no difference from placebo.
What makes the failure particularly vexing is that the drug did what it was designed to do mechanistically. Ziltivekimab lowered interleukin-6 and hsCRP levels as expected, yet no clinical benefit followed. Compounding the disappointment, serious infections occurred more frequently in the treatment arm, while overall mortality showed no difference between groups. Novo has confirmed a non-cash impairment charge will hit the third quarter, though the full-year 2026 guidance remains intact.
The asset arrived via the 2020 acquisition of Corvidia Therapeutics, a deal valued at $725 million upfront with up to an additional $2.1 billion in potential milestone payments. Those milestones now look increasingly distant, though Novo is keeping two other studies alive: HERMES, examining the drug in heart failure, and ARTEMIS, focused on acute myocardial infarction. Results from both are expected in the first half of 2027 and will likely determine whether the cardiology program has any future at all.
Analysts Split on Whether the Market Overreacted
Wall Street is divided on the severity of Friday’s move. UBS analyst Matthew Weston called the outcome unambiguously negative, noting his bank had modeled 60 percent of Ziltivekimab’s potential $3 billion peak sales into its valuation. Weston expects the market reaction to overshoot the pure valuation impact by a factor of two to three.
Jefferies and Citi see it differently, arguing the sell-off was disproportionate given the drug’s small share of Novo’s overall portfolio. But even those houses acknowledge a strategic cost: Ziltivekimab represented a credible growth avenue beyond obesity and diabetes, and that optionality has now evaporated. Mizuho’s Jared Holz describes the data as a blow to pipeline sentiment while maintaining that the oral Wegovy tablet’s momentum leaves Novo reasonably positioned heading into Wednesday’s report.
The consensus analyst rating sits at “Hold” with a price target near $47, and the market’s aggregate reaction — a loss of more than $30 billion in market value on Friday — strikes many observers as out of step with the drug’s actual revenue contribution.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Valuation at Historic Lows, But the Clock Is Ticking
The failed trial has collided with an already cautious outlook to produce a valuation rarely seen in Novo’s recent history. The stock now trades at a price-to-earnings ratio of just 11, near its historic trough. For value-oriented investors, that looks like an entry point into a GLP-1 market with undeniable long-term growth. For skeptics, it reflects justified concern about a company whose near-term momentum has stalled.
The second quarter marks the first full reporting period capturing broader market penetration of the oral Wegovy tablet beyond its initial launch countries. The EU approved the pill earlier this year, along with a higher-dose 7.2-milligram variant in mid-July, opening additional growth avenues. Novo’s oral Wegovy has maintained roughly 89 percent of U.S. oral GLP-1 volume since its January launch, even as Eli Lilly published positive Phase 3 data for its competing candidate Retatrutid on July 23.
But the company’s own guidance has tempered enthusiasm: Novo has projected a decline in both revenue and operating profit for 2026, a signal that the GLP-1 business lacks near-term acceleration. The earnings estimates reflect that caution — analysts expect EPS of $0.81, down 16.5 percent year over year, with other forecasts pointing to revenue of DKK 71.5 billion and EPS of DKK 5.04, both below prior-year levels.
A History of Weak Q2 Reactions
The options market’s 8 percent implied move is not without precedent, and the history cuts against Novo. In each of the past two years, the stock fell on the day of its Q2 report — by 6.7 percent in 2024 and 5.4 percent in 2025. Saxo Bank analysts see a pattern: good news is largely priced in, while the track record of disappointing reactions to second-quarter prints argues for caution. In their view, the downside risk deserves at least as much respect as the possibility of an upside surprise.
The stock currently sits roughly 25 percent below its 52-week high of EUR 54.86 from January, and the year-to-date decline stands at just over 7 percent. The technical picture, while dented, hasn’t collapsed — the close above the 200-day average suggests the medium-term uptrend remains intact, if scratched.
Beyond the Numbers: Lawsuits and Buybacks
Operational developments continue alongside the clinical and financial drama. Late July brought a lawsuit against Eli Lilly over allegedly misleading advertising for its GLP-1 products, adding a legal dimension to the competitive rivalry. Meanwhile, Novo is running a share buyback program of up to $2.3 billion, of which roughly $1.10 billion had been deployed as of July 24.
Chief Scientific Officer Martin Holst Lange told CNBC that the ZEUS outcome doesn’t alter the company’s strategic commitment to cardiology. Whether that commitment translates into future value, however, depends on the HERMES and ARTEMIS readouts — and on whether Wednesday’s earnings can demonstrate that the core GLP-1 engine still has the power to drive the story forward. The report will show whether the recent stabilization in Wegovy demand can hold its own against a year defined by pipeline setbacks. For a company trading at historic valuation lows, the stakes could hardly be higher.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 1 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 1.
Novo Nordisk: Buy or sell? Read more here...
